Date:12/21/2010

required by law. Contacts:For CypressFor RamiusFor Royalty PharmaMatthew Sherman or
Dara Silverstein
212-355-4449
both of Joele Frank, Wilkinson
Brimmer Katcher
Amy Bilbija or Bob Marese
212-929-5500
both of MacKenzie Partners, Inc. Peter Feld,
212-201-4878, or
Gavin Molinelli
212-201-4828
both of Ramius LLC Pablo Legorreta
212-883-2289, or
Alexander V. Perfall
212-883-2298
'/>"/>

SOURCE Ramius V&O Acquisition LLC Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cypress Bioscience Board of Directors to Review Unsolicited Tender Offer from Ramius LLC
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
4. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
5. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
6. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
7. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia